College Fails To Get More Royalties From Merck Drug

Law360, New York (July 28, 2010, 4:29 PM EDT) -- A federal appeals court has ruled that the University of Illinois tried too late to reverse an arbitrator's unfavorable decision in a dispute with a subsidiary of Merck & Co. over an intellectual property license for a cancer drug.

The U.S. Court of Appeals for the Seventh Circuit on Tuesday ended the university's hopes of squeezing more royalties from Organon Teknika Corp. LLC, which licensed intellectual property from the university to make Tice BCG.

The university's royalties are determined by sales to Organon customers, and the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.